Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · IEX Real-Time Price · USD
8.47
-0.12 (-1.40%)
At close: Apr 26, 2024, 4:00 PM
8.31
-0.16 (-1.89%)
After-hours: Apr 26, 2024, 7:55 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for ARQT stock have an average target of 27.71, with a low estimate of 10 and a high estimate of 50. The average target predicts an increase of 227.15% from the current stock price of 8.47.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ARQT stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 3 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +88.90% | Apr 12, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $6 → $11 | Hold | Maintains | $6 → $11 | +29.87% | Feb 28, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $16 → $17 | Strong Buy | Reiterates | $16 → $17 | +100.71% | Feb 28, 2024 |
| Needham | Needham | Strong Buy Maintains $8 → $16 | Strong Buy | Maintains | $8 → $16 | +88.90% | Feb 28, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $8 → $16 | Strong Buy | Reiterates | $8 → $16 | +88.90% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
107.38M
from 59.61M
Increased by 80.15%
Revenue Next Year
218.24M
from 107.38M
Increased by 103.24%
EPS This Year
-2.56
from -3.78
EPS Next Year
-1.49
from -2.56
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 128.6M | 261.5M | 454.6M | 684.9M | 930.3M |
| Avg | 107.4M | 218.2M | 369.6M | 524.3M | 683.6M |
| Low | 73.5M | 161.7M | 310.5M | 422.2M | 511.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 115.8% | 143.5% | 108.3% | 85.3% | 77.5% |
| Avg | 80.1% | 103.2% | 69.4% | 41.8% | 30.4% |
| Low | 23.3% | 50.6% | 42.3% | 14.2% | -2.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.32 | -1.12 | 0.30 | 2.66 | 4.13 |
| Avg | -2.56 | -1.49 | -0.33 | 0.95 | 1.98 |
| Low | -3.08 | -1.91 | -0.74 | -0.14 | 0.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 335.0% |
| Avg | - | - | - | - | 108.6% |
| Low | - | - | - | - | -91.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.